Targeting PFKFB3 may therefore represent a promising therapeutic strategy to disrupt tumor–macrophage crosstalk and impede cancer progression, although the metabolic plasticity of TAMs suggests that combination therapies addressing multiple pathways may be necessary to fully overcome tumor-induced immunosuppression. The gene discussed is PFKFB3; the disease is neoplasm.